07-May-2012 - Evotec SE

Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA)

Evotec AG announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. The contract covers a period of five years and has a total value of up to EUR7.7 million (approx. USD 10 million).

Under the agreement Evotec, through its San Francisco operations, will provide chemical procurement, analysis, sample preparation, and management services in support of the EPA's National Computational Center for Toxicology (NCCT). Services provided will support bioactivity profiling of the EPA's ToxCast(TM) (Prioritization of Environmentally Relevant Chemicals) Compound Library.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are very pleased that the United States EPA has again chosen Evotec to manage its compound collection in support of the National Computational Center for Toxicology (NCCT). This follows from our initial contract with the EPA signed in 2007. Providing key, efficient scientific infrastructures such as Compound Management is a key element of Evotec Execute and we look forward to supporting the EPA's ongoing effort to predict potential toxicity of environmental chemicals. This contract provides further long-term revenue and profitability for Evotec's important compound management services in San Francisco which was acquired from BioFocus in 2011."

Facts, background information, dossiers
More about Evotec
  • News

    PerkinElmer Completes Acquisition of Euroscreen Products SA And Evotec Technologies

    PerkinElmer, Inc. reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis and High Content Screening (HCS). In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen ... more

    PerkinElmer to Acquire Evotec Technologies

    PerkinElmer, Inc. announced that it has signed a definitive agreement with Evotec AG to acquire its majority owned subsidiary, Evotec Technologies GmbH, in a cash transaction valued at approximately EUR 23 million. The transaction is subject to regulatory approvals and other customary closi ... more

    Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services

    Evotec AG and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the agreements, P&GP ... more

  • Companies

    Evotec SE

    Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In a ... more

More about Environmental Protection Agency